| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Collaboration revenue | 3,985,754 | - |
| Total research and development expenses | 11,794,054 | - |
| In-process research and development | 515,996 | - |
| Total general and administrative expenses | 8,179,521 | - |
| Depreciation | 20,520 | - |
| Other income | 1,006,772 | - |
| Net loss | -15,517,565 | -13,401,734 |
| Depreciation | 20,520 | 13,680 |
| Stock-based compensation, including the issuance of restricted stock | 3,186,687 | 2,115,795 |
| Acquired in-process research and development assets | 515,996 | - |
| Prepaids and other current assets | -2,073,722 | -2,298,347 |
| Accounts payable | -476,426 | -656,784 |
| Accrued expenses | 250,646 | 1,450,625 |
| Deferred collaboration revenue | 214,246 | -421,500 |
| Net cash used in operating activities | -9,732,174 | -8,601,571 |
| Purchase of in-process research and development assets | 515,996 | - |
| Net cash used in investing activities | -515,996 | - |
| Proceeds from the exercise of stock options | 38,274 | 19,137 |
| Net cash provided by financing activities | 38,274 | 19,137 |
| Net decrease in cash and cash equivalents | -10,209,896 | -8,582,434 |
| Cash and cash equivalents at beginning of period | 38,339,762 | - |
| Cash and cash equivalents at end of period | 28,129,866 | - |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)